Copper-67 vs lutetium-177 manufacturing

Clarity is committed to developing next-generation radiopharmaceuticals that provide safe and effective treatments for patients and offer a reliable, scalable and environmentally friendly solution to manufacturing and supply chain issues plaguing the current generation of products.
Being able to not only develop, but also successfully deliver life changing radiopharmaceuticals to a large number of cancer patients is essential for radiopharmaceuticals to grow in the large oncology market and improve lives of people with this insidious disease.
Cu-67 is produced in high quantities on electricity-powered electron accelerators, a process that is easily scalable to reach the future demand for radiopharmaceuticals globally. This is in contrast to the current process for producing Lu-177, which is reliant on an aging fleet of uranium-powered nuclear reactors that experience frequent and prolonged maintenance shutdowns, leading to shortages of these essential cancer treatments.
Watch the video to learn more about the differences in the Cu-67 and Lu-177 manufacturing process and the numerous benefits the production and supply of Cu-67 can achieve.

[@maddysydney]

Alan delivers the sucker punch, time and again😂